Beam Therapeutics director granted stock options

Beam Therapeutics director Christi Shaw received a grant of stock options, giving the right to buy 19,676 shares of Common Stock at an exercise price of $29.55 per share.

Rhea-AI Filing Summary

Beam Therapeutics director Christi Shaw received a grant of stock options, giving the right to buy 19,676 shares of Common Stock at an exercise price of $29.55 per share. The options vest in full on the earlier of one year from grant or immediately before the next annual stockholders' meeting, contingent on continued board service, and expire on June 3, 2036. After this grant, 19,676 derivative securities are reported as held directly.

Insider Trade Summary

Grant/Award: 19,676 shares

Grant/Award 1 txn

Insider Shaw Christi

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,676	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,676 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

Key Figures

Option grant size: 19,676 options Exercise price: $29.55 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 19,676 options Stock Option (Right to Buy) granted to director Christi Shaw

Exercise price $29.55 per share Exercise price for Beam Therapeutics stock options

Expiration date June 3, 2036 Options expire on this date if not exercised

Shares underlying options 19,676 shares Underlying Common Stock for the option grant

Holdings after grant 19,676 derivative securities Total options held directly following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 29.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests in full on the earlier of the first anniversary..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"immediately prior to the date of the next year's annual meeting of stockholders"

derivative securities financial

"derivativeTransactionCount: 1, derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics (BEAM) director Christi Shaw report on this Form 4?

Beam Therapeutics director Christi Shaw reported receiving a grant of stock options covering 19,676 shares of Common Stock at a $29.55 exercise price. This is a compensation-related award, not an open-market stock purchase or sale.

How many Beam Therapeutics (BEAM) shares are covered by the new stock options?

The new stock option grant covers 19,676 shares of Beam Therapeutics Common Stock. These are derivative securities that, if exercised in the future, would allow purchase of an equal number of common shares at the preset exercise price.

What is the exercise price and expiration date of Christi Shaw’s Beam (BEAM) options?

The options have an exercise price of $29.55 per share and expire on June 3, 2036. This means the director can choose to buy shares at $29.55 any time before that expiration date, once the options are vested.

When do Christi Shaw’s Beam Therapeutics (BEAM) option awards vest?

The option award vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholders’ meeting. Vesting requires Christi Shaw to remain in service on Beam Therapeutics’ board through that vesting date.

Is Christi Shaw buying or selling Beam Therapeutics (BEAM) stock in this filing?

This filing does not show an open-market buy or sell of Beam Therapeutics stock. It reports a grant of stock options as compensation, classified as an acquisition of derivative securities rather than a market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shaw Christi

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$29.55	06/03/2026		A		19,676		(1)	06/03/2036	Common Stock	19,676	$0	19,676	D

Explanation of Responses:

1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)